Drugdocs | Creon®

Drug updated on 4/17/2024

Dosage Form	Capsule (oral; lipase/protease/amylase [3,000 USP/9,500 USP/15,000 USP], [6,000 USP/19,000 USP/30,000 USP], [120,000 USP/38,000 USP/60, 000 USP], [24,000 USP, 76,000 USP, 120,000 USP], [36,000 USP, 114,000 USP, 180,000 USP])
Drug Class	Digestive enzymes
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Pancrelipase (Creon) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
The information was derived from a single study which is a systematic review/meta-analysis.
In terms of effectiveness, Creon improves PEI-related malabsorption and supports weight maintenance across several patient groups including those with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-surgical states.
For patients suffering from chronic pancreatitis specifically, Creon also alleviates PEI-related symptoms.
When compared to general treatment strategies for exocrine pancreatic insufficiency (PEI), Creon demonstrates superior safety and efficacy profiles according to the reviewed study.
The proven benefits of Creon in various population types and subgroups are highlighted.

Document Title	Year	Source
Creon (pancrelipase) Prescribing Information.	2024	AbbVie Inc. North Chicago, IL

Document Title	Year	Source
Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency.	2019	World Journal of Gastroenterology

Document Title	Year	Source
Evidence-based clinical practice guidelines for chronic pancreatitis 2021.	2022	Journal of Gastroenterology